China-based Sciwind Biosciences has submitted a Hong Kong Stock Exchange (HKEX) initial public offering (IPO) application with Morgan Stanley and China International Capital Corporation as sponsors, seeking funding for commercialisation of first-in-class cAMP-biased GLP-1 receptor agonist enoglutide for obesity and type two diabetes (T2D). The candidate demonstrated 15.1% placebo-adjusted weight loss in Phase III trials, outperforming semaglutide's 8.5% reduction with 92.8% patients achieving clinically meaningful weight loss versus 54.3% to 88% for competitors. Enoglutide's selective cAMP activation reduces beta-arrestin recruitment, minimising receptor desensitisation for sustained efficacy.

Sciwind's pipeline includes oral GLP-1 agonist XW004 with 3- to 5-fold higher bioavailability than existing oral peptides, showing 6.8% weight loss in six weeks versus 2.3% for Novo Nordisk's oral semaglutide and 4.3% for orforglipron. The company's technology platforms include BiasVantage for biased agonist design, Oralvantage for peptide absorption enhancement and HaleVantage for half-life extension through fatty acid modification and antibody-peptide conjugation. Sciwind has partnerships with HK inno.N Corporation, Verdiva Bio and Sino Biopharm for specific indication development leveraging partner commercial networks.

According to PharmCube's MedAlpha® database, Sciwind's IPO application comes after six funding rounds over the past decade. Click here to request a free trial for MedAlpha®.